Barclays’s ProShares Ultra Health Care RXL Stock Holding History

Barclays’s Portfolio RXL Stock Details RXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,124	Closed	-$52K	–	4969
2021 Q2	$52K	Buy	+1,124	New	+$49.1K	﹤0.01%	4114

Other funds holding RXL

IAN

Integrated Advisors Network Dallas, Texas $1.91B AUM 24.91% 1-Year Est. Return

IMC Chicago Chicago, Illinois $278B AUM 44.93% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return

OMC

Old Mission Capital Chicago, Illinois $6.3B AUM 14.68% 1-Year Est. Return

Sprott Inc Toronto, Ontario, Canada $3.44B AUM 125.26% 1-Year Est. Return

TFA

Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return

Barclays's RXL Position: Q3 2021 in Review

Barclays sold out of ProShares Ultra Health Care (RXL) in Q3 2021, closing a stake of 1,124 shares — an estimated $52K sold.

Barclays first reported a position in RXL in Q2 2021 and held it in 1 quarter. The position peaked at $52K in Q2 2021. 25 funds tracked by Wall St. Rank hold RXL as of Q3 2021.

Barclays reported no remaining ProShares Ultra Health Care position as of Q3 2021 after selling out during the quarter.
Barclays sold 1,124 ProShares Ultra Health Care shares in Q3 2021, an estimated $52K.
Barclays first reported a position in ProShares Ultra Health Care in Q2 2021 and held it in 1 quarter.
Barclays's ProShares Ultra Health Care position peaked at $52K in Q2 2021.
25 funds tracked by Wall St. Rank held ProShares Ultra Health Care as of Q3 2021.

Based on Barclays's 13F filing for Q3 2021, filed 9 Nov 2021.